All In Biotech

Free tool

FAERS Monitor: Inlyta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 202324 or its brand name (Inlyta, Axitinib). Reports on generic versions are filed under their own applications.

Reports

19,549

Serious

12,971

66% of reports

Hospitalization

5,052

Death reported

3,948

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death2,699
  • diarrhoea2,594
  • fatigue2,123
  • hypertension1,331
  • neoplasm progression1,324
  • disease progression1,211
  • off label use1,207
  • nausea1,145
  • decreased appetite1,094
  • dysphonia1,013
  • blood pressure increased855
  • weight decreased806
  • asthenia765
  • headache604
  • stomatitis594

Reports by year received

View as table
YearReports
20081
200918
201032
201128
2012569
20131,060
20141,157
20151,094
2016814
2017766
2018697
20191,160
20202,413
20212,270
20222,688
20231,907
20241,429
2025889
2026557

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,034,610 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
neoplasm progressionSignal1,32442.640.451,732
dysphoniaSignal1,01318.917.816,949
disease progressionSignal1,21111.110.511,085
stomatitisSignal59410.69.85,137
hypertensionSignal1,3316.86.56,601
blood pressure increasedSignal8556.05.73,601
decreased appetiteSignal1,0945.14.83,611
diarrhoeaSignal2,5944.34.26,840
deathSignal2,6993.43.34,694
weight decreasedSignal8063.12.91,166
fatigueSignal2,1232.92.82,811
astheniaSignal7652.22.0502
nausea1,1451.61.5236
off label use1,2071.51.4198
headache6041.01.01

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.